期刊文献+

非布司他治疗痛风伴高尿酸血症的临床疗效探讨 被引量:3

下载PDF
导出
摘要 目的探讨非布司他治疗痛风伴高尿酸血症的临床效果。方法选取我院2016年1月—7月收治的60例痛风伴高尿酸血症患者作为研究对象,将其随机分为观察组和对照组,各30例。对照组给予别嘌醇治疗,观察组给予非布司他治疗,2组患者疗程均为20周。治疗前后分别检测2组患者血尿酸,并记录20周后血尿酸水平<360μmol/L的例数。结果2组患者治疗后血尿酸水平均较治疗前有所下降,且观察组患者血尿酸水平明显低于对照组;观察组中更多患者的血尿酸水平达到了低于360μmol/L的控制目标,差异具有统计学意义(P<0.05)。结论将非布司他用于痛风伴高尿酸血症患者的临床治疗,能有效降低血尿酸水平,效果显著,安全性较高,值得推广。
出处 《基层医学论坛》 2017年第22期2950-2951,共2页 The Medical Forum
  • 相关文献

参考文献6

二级参考文献87

  • 1陈光亮,王琳琳,徐叔云.防治痛风的药物研究进展[J].国外医学(内分泌学分册),2005,25(4):277-279. 被引量:15
  • 2朱深银,周远大,杜冠华.防治痛风药物的研究进展[J].医药导报,2006,25(8):803-806. 被引量:31
  • 3Takano Y,Hase-Aoki K,Horiuchi H,et al.Selectivity of febuxostat,a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.Life Sci,2005,76(16):1835-1847.
  • 4Bruce SP.Febuxostat:a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.Ann Pharmacother,2006,40(12):2187-2194.
  • 5Mayer MD,Khosravan R,Vernillet L,et al.Pharmacokinetics and pharmacodynamics of febuxostat,a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment.Am J Ther,2005,12(1):22-34.
  • 6Khosravan R,Grabowski BA,Wu JT,et al.Pharmacokinetics,pharmacodynamics and safety of febuxostat,a non-purine selective inhibitor of xanthine oxidase,in a dose escalation study in healthy subjects.Clin Pharmacokinet,2006,45(8):821-841.
  • 7Khosravan R,Grabowski BA,Mayer MD,et al.The effect of mild and moderate hepatic impairment on pharmacokinetics,pharmacodynamics,and safety of febuxostat,a novel nonpurine selective inhibitor of xanthine oxidase.J Clin Pharmacol,2006,46(1):88-102.
  • 8Becker MA,Schumacher HR,Wortmann RL,et al.Febuxostat,a novel nonpurine selective inhibitor of xanthine oxidase:a twenty-eight-day,multicenter,phaseⅡ,randomized,double-blind,placebo-controlled,dose-response clinical trial examining safety and efficacy in patients with gout.Arthritis Rheum,2005,52(3):916-923.
  • 9Schumacher HR,Becker MA,Wortmann RL,et al.Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout:a 28-week,phase Ⅲ,randomized,double-blind,parallel-group trial.Arthritis Rheum,2008,59(11):1540-1548.
  • 10Becker MA,Schumacher HR,Wortmann RL,et al.Febuxostat compared with allopurinol in patients with hyperuricemia and gout.N Engl J Med,2005,353(23):2450-2461.

共引文献112

同被引文献29

引证文献3

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部